Chief Executive Officer, Economic Development Innovations
Singapore (EDIS)​
Group Chief Executive Officer, Advanced MedTech Holdings

Mr Abel Ang is the Group Chief Executive Officer of Advanced MedTech Holdings, a US$200M global player in Urology devices and services.

Mr Ang has a proven track record in the medical device sector. He has served as the Senior Advisor to the CEO of Greatbatch Inc (NYSE: ITGR), providing guidance relative to the commercialization of medical device technologies in the cardiac, neurology, vascular and orthopaedic markets. Prior to Greatbatch, Mr. Ang was President, Asia/Pacific for Hill-Rom Inc. a US$3B revenue medical devices company (NYSE: HRC) where he was responsible for leading, developing and implementing the strategy to expand Hill-Rom’s presence in the Asia/Pacific markets. He formerly served as the Chief Technology Officer for Hill-Rom for 3 years. In that role he had overall responsibility for Hill-Rom’s global R&D operations which are distributed across sites in the U.S., Mexico, France, and Singapore. At Hill-Rom, he also held the positions of Vice-President and General Manager of Hill-Rom’s US$420M Global Surfaces and Therapy Business Unit; and Vice-President for International Business and Technology Development. He formerly headed the global Medical Technology and Biotechnology industry groups in the Singapore Economic Development Board’s (EDB) Biomedical Division.

Mr Ang sits on the Board of Economic Development Innovations Singapore, a privately-held company headquartered in Singapore with offices in Germany and the US. With expertise honed in conceiving and managing townships in India, Vietnam, China and Indonesia, EDIS’ core business is in investing, managing and developing integrated cities globally. Ang also sits on the Board of Accelerate Technologies which provides access to Singapore's largest pool of intellectual property and knowledge generated by over 2,000 researchers at A*STAR's research institutes. In addition, he sits on the Boards of the following Advanced MedTech operating and investment companies: Dornier MedTech, AMT Pte Ltd, AWAK Technologies, Advent Access. He was formerly on the Board and Nominating Committee of Aslan Pharmaceuticals (NYSE: ASLN).

Mr Ang is an Adjunct Professor at the Nanyang Business School in Singapore and Waseda University in Japan, where he teaches in their respective MBA programmes.

Mr Ang has a Master of Science in Computational Biology from Rutgers University in New Jersey, which he pursued while on an EDB scholarship. He attended Harvard Business School’s Advanced Management Program in 2012.